These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10555932)

  • 21. Study of renal safety in amphotericin B lipid complex-treated patients.
    Alexander BD; Wingard JR
    Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
    Cagnoni PJ
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():81-6. PubMed ID: 11801587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP; Garey KW; Danziger LH
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP
    Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
    J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
    Palmer SM; Drew RH; Whitehouse JD; Tapson VF; Davis RD; McConnell RR; Kanj SS; Perfect JR
    Transplantation; 2001 Aug; 72(3):545-8. PubMed ID: 11502995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients.
    Merhav H; Mieles L
    Transplant Proc; 1997 Sep; 29(6):2670-4. PubMed ID: 9290785
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
    Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
    Collazos J; Martínez E; Mayo J; Ibarra S
    Clin Infect Dis; 2001 Oct; 33(7):E75-82. PubMed ID: 11528589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
    Walsh TJ; Whitcomb P; Piscitelli S; Figg WD; Hill S; Chanock SJ; Jarosinski P; Gupta R; Pizzo PA
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1944-8. PubMed ID: 9303390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
    Perfect JR
    Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).
    Ito JI; Chandrasekar PH; Hooshmand-Rad R
    Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex.
    Kline S; Larsen TA; Fieber L; Fishbach R; Greenwood M; Harris R; Kline MW; Tennican PO; Janoff EN
    Clin Infect Dis; 1995 Nov; 21(5):1154-8. PubMed ID: 8589135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
    Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
    Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
    Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
    Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.